Sybil A. McAuley

Sybil A. McAuley

Auto-generated profile, based on publicly available information

Sybil A. McAuley

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
SMSybil A. McAuley
Sybil A. McAuley
STSteven Trawley
Steven Trawley
SVSara Vogrin
Sara Vogrin
GWGlenn M. Ward
Glenn M. Ward
SFSpiros Fourlanos
Spiros Fourlanos
RMRichard MacIsaac
Richard MacIsaac
OBJECTIVE To assess the efficacy and safety of closed-loop insulin delivery compared with sensor-augmented pump therapy among older adults with type 1 diabetes. RESEARCH DESIGN AND METHODS This open-label, randomized (1:1), crossover trial compared 4 months of closed-loop versus sensor-augmented pump therapy. Eligible adults were aged ≥60 years, with type 1 diabetes (duration ≥10 years), using an insulin pump. The primary outcome was continuous glucose monitoring (CGM) time in range (TIR; 3.9–10.0 mmol/L). RESULTS There were 30 participants (mean age 67 [SD 5] years), with median type 1 diabetes duration of 38 years (interquartile range [IQR] 20–47), randomized (n = 15 to each sequence); all completed the trial. The mean TIR was 75.2% (SD 6.3) during the closed-loop stage and 69.0% (9.1) during the sensor-augmented pump stage (difference of 6.2 percentage points [95% CI 4.4 to 8.0]; P < 0.0001). All prespecified CGM metrics favored closedloop over the sensor-augmented pump; benefits were greatest overnight. Closedloop reduced CGM time <3.9 mmol/L during 24 h/day by 0.5 percentage points (95% CI 0.3 to 1.1; P = 0.0005) and overnight by 0.8 percentage points (0.4 to 1.1; P < 0.0001) compared with sensor-augmented pump. There was no significant difference in HbA1c between closed-loop versus sensor-augmented pump stages (7.3% [IQR, 7.1–7.5] (56 mmol/mol [54–59]) vs. 7.5% [7.1–7.9] (59 mmol/mol [54–62]), respectively; P = 0.13). Three severe hypoglycemia events occurred during the closed-loop stage and two occurred during the sensor-augmented pump stage; no hypoglycemic events required hospitalization. One episode of diabetic ketoacidosis occurred during the sensor-augmented pump stage; no serious adverse events occurred during the closed-loop stage. CONCLUSION Closed-loop therapy is an effective treatment option for older adults with long-duration type 1 diabetes, and no safety issues were identified. These older adults had higher TIR accompanied by less time below range during closedloop than during sensor-augmented pump therapy. Of particular clinical importance, closed loop reduced the time spent in hypoglycemic range overnight.

13 August 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
Giuseppe MalteseGiuseppe Maltese
Giuseppe Maltese
SMSybil A. McAuley
Sybil A. McAuley
STSteven Trawley
Steven Trawley
ASAlan J. Sinclair
Alan J. Sinclair
Over the past two decades there has been a substantial rise in the adoption of diabetes therapeutic technology among children, adolescents and younger adults with type 1 diabetes, and its use is now also advocated for older individuals. Older people with diabetes are more prone to experience hypoglycaemia because of numerous predisposing factors and are at higher risk of hypoglycaemic events requiring third-party assistance as well as other adverse sequelae. Hypoglycaemia may also have long-term consequences, including cognitive impairment, frailty and disability. Diabetes in older people is often characterised by marked glucose variability related to age-associated changes such as variable appetite and levels of physical activity, comorbidities and polypharmacotherapy. Preventing hypoglycaemia and mitigating glucose excursions may have considerable positive impacts on physical and cognitive function and general well-being and may even prevent or improve frailty. Technology for older people includes continuous glucose monitoring systems, insulin pumps, automated insulin delivery systems and smart insulin pens. Clinical trials and real-world studies have shown that older people with diabetes benefit from technology in terms of glucose management, reductions in hypoglycaemic events, emergency department attendance and hospital admissions, and improvement in quality of life. However, ageing may bring physical impairments and other challenges that hinder the use of technology. Healthcare professionals should identify older adults with diabetes who may benefit from therapeutic technology and then adopt an individualised approach to education and follow-up for individuals and their caregivers. Future research should explore the impact of diabetes technology on outcomes relevant to older people with diabetes. Graphical Abstract

17 November 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
BPBarbora Paldus
Barbora Paldus
DMDale Morrison
Dale Morrison
DZDessi P. Zaharieva
Dessi P. Zaharieva
MLMelissa H. Lee
Melissa H. Lee
HJHannah Jones
Hannah Jones
DODavid N. O’nEal
David N. O’nEal
OBJECTIVE To compare glucose control with hybrid closed-loop (HCL) when challenged by high intensity exercise (HIE), moderate intensity exercise (MIE), and resistance exercise (RE) while profiling counterregulatory hormones, lactate, ketones, and kinetic data in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS Open-label multisite randomized crossover trial. Adults with type 1 diabetes undertook 40 min of HIE, MIE, and RE in random order while using HCL (Medtronic MiniMedTM 670G) with a temporary target set 2 h prior to and during exercise and 15 g carbohydrates if pre-exercise glucose was <126 mg/dL to prevent hypoglycemia. Primary outcome was median (interquartile range) continuous glucose monitoring time-in-range (TIR; 70–180 mg/dL) for 14 h post–exercise commencement. Accelerometer data and venous glucose, ketones, lactate, and counterregulatory hormones were measured for 280 min post–exercise commencement. RESULTS Median TIR was 81% (67, 93%), 91% (80, 94%), and 80% (73, 89%) for 0–14 h post–exercise commencement for HIE, MIE, and RE, respectively (n = 30), with no difference between exercise types (MIE vs. HIE; P = 0.11, MIE vs. RE, P = 0.11; and HIE vs. RE, P = 0.90). Time-below-range was 0% for all exercise bouts. For HIE and RE compared with MIE, there were greater increases, respectively, in noradrenaline (P = 0.01 and P = 0.004), cortisol (P < 0.001 and P = 0.001), lactate (P ≤ 0.001 and P ≤ 0.001), and heart rate (P = 0.007 and P = 0.015). During HIE compared with MIE, there were greater increases in growth hormone (P = 0.024). CONCLUSIONS Under controlled conditions, HCL provided satisfactory glucose control with no difference between exercise type. Lactate, counterregulatory hormones, and kinetic data differentiate type and intensity of exercise, and their measurement may help inform insulin needs during exercise. However, their potential utility as modulators of insulin dosing will be limited by the pharmacokinetics of subcutaneous insulin delivery.

3 December 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MLMelissa H. Lee
Melissa H. Lee
SVSara Vogrin
Sara Vogrin
BPBarbora Paldus
Barbora Paldus
DJDilshani Jayawardene
Dilshani Jayawardene
HJHannah M. Jones
Hannah M. Jones
DODavid N. O’nEal
David N. O’nEal
OBJECTIVE To evaluate exercise-related glucose and counterregulatory responses (CRR) in adults with type 1 diabetes with impaired awareness of hypoglycemia (IAH) using hybrid closed-loop (HCL) insulin delivery to maintain glucose homeostasis. RESEARCH DESIGN AND METHODS Twelve participants undertook 45-min high-intensity intermittent exercise (HIIE) and moderate-intensity exercise (MIE) in random order. The primary outcome was continuous glucose monitoring (CGM) time in range (70–180 mg/dL) for 24-h post–exercise commencement. RESULTS CGM time in range was similar for HIIE and MIE (median 79.5% [interquartile range 73.2, 87.6] vs. 76.1% [70.3, 83.9], P = 0.37), and time with levels <54mg/dL post–exercise commencement was 0%. HIIE induced greater increases in cortisol (P = 0.002), noradrenaline (P = 0.005), and lactate (P = 0.002), with no differences in adrenaline, dopamine, growth hormone, or glucagon responses. CONCLUSIONS IAH adults using HCL undertaking HIIE and MIE exhibit heterogeneity in CRR. Novel findings were a preserved cortisol response and variable catecholamine responses to HIIE.

15 December 2022 in Diabetic Medicine
Verified
Journal Article
Open access
EKErin Kubilay
Erin Kubilay
STSteven Trawley
Steven Trawley
GWGlenn M. Ward
Glenn M. Ward
SFSpiros Fourlanos
Spiros Fourlanos
CGCharlotte A. Grills
Charlotte A. Grills
SMSybil A. McAuley
Sybil A. McAuley
Aim: To explore the lived experience of older adults with type 1 diabetes using closed‐loop automated insulin delivery, an area previously receiving minimal attention.Methods: Semi‐structured interviews were conducted with adults aged 60 years or older with long‐duration type 1 diabetes who participated in a randomised, open‐label, two‐stage crossover trial comparing first‐generation closed‐loop therapy (MiniMed 670G) versus sensor‐augmented pump therapy. Interview recordings were transcribed, thematically analysed and assessed.Results: Twenty‐one older adults participated in interviews after using closed‐loop therapy. Twenty were functionally independent, without frailty or major cognitive impairment; one was dependent on caregiver assistance, including for diabetes management. Quality of life benefits were identified, including improved sleep and reduced diabetes‐related psychological burden, in the context of experiencing improved glucose levels. Gaps between expectations and reality of closed‐loop therapy were also experienced, encountering disappointment amongst some participants. The cost was perceived as a barrier to continued closed‐loop access post‐trial. Usability issues were identified, such as disruptive overnight alarms and sensor inaccuracy.Conclusions: The lived experience of older adults without frailty or major cognitive impairment using first‐generation closed‐loop therapy was mainly positive and concordant with glycaemic benefits found in the trial. Older adults' lived experience using automated insulin delivery beyond trial environments requires exploration; moreover, the usability needs of older adults should be considered during future device development.

24 August 2022 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
ACAnindita Chakrabarti
Anindita Chakrabarti
STSteven Trawley
Steven Trawley
EKErin Kubilay
Erin Kubilay
AAAndisheh Mohammad Alipoor
Andisheh Mohammad Alipoor
SVSara Vogrin
Sara Vogrin
SMSybil A. McAuley
Sybil A. McAuley
Sleep-related effects of closed-loop therapy among older adults with type 1 diabetes have not been well established. In the OldeR Adult Closed-Loop (ORACL) randomized, crossover trial of first-generation closed-loop therapy (MiniMed 670G), participants wore actigraphy and completed sleep diaries for 14-day periods at stage end. During objectively measured sleep (actigraphy) with closed-loop versus sensor-augmented pump therapy, glucose time-in-range 70–180 mg/dL (3.9–10.0 mmol/L) was greater (90.3% vs. 78.7%, respectively; difference 8.2 percentage points [95% confidence interval {CI} 1.5 to 13.0]; P = 0.008), and there were fewer sensor hypoglycemia episodes (18 vs. 43, respectively; incident rate ratio 0.40 [95% CI 0.20 to 0.55]; P = 0.007). Sleep quality recorded daily was worse with closed-loop therapy ( P = 0.006); Pittsburgh Sleep Quality Index did not differ. There were 30% more system alarms during monitored sleep with closed-loop therapy ( P < 0.001). First-generation closed-loop therapy has important glycemic benefits during sleep for older adults, with deterioration in some sleep quality measures. Sleep quality warrants prioritization and investigation during advancement of closed-loop technology.